Is the use of biologic therapy safe and FDA‑approved for treating severe plaque psoriasis in a patient who is hepatitis C antibody (HCV Ab) positive?

Biologic Therapy in HCV Antibody-Positive Patients with Severe Plaque Psoriasis

Yes, biologic therapy is safe and FDA-approved for treating severe plaque psoriasis in HCV antibody-positive patients, and can be used with appropriate monitoring. 1

FDA Approval Status

All major biologics for psoriasis (TNF-α inhibitors, IL-12/23 inhibitors like ustekinumab, IL-17 inhibitors, and IL-23 inhibitors) are FDA-approved for moderate-to-severe plaque psoriasis without specific exclusions for HCV antibody-positive patients 1.

Safety Profile in HCV-Positive Patients

Guideline Recommendations

The 2019 Joint AAD-NPF Guidelines explicitly state: "In patients with a history of or currently active hepatitis C, ustekinumab might be considered for the treatment of psoriasis." 1 This represents a clear endorsement from the highest-quality guideline available.

For TNF-α inhibitors, the guidelines recommend using caution in patients with pre-existing immunosuppression-related conditions but do not contraindicate their use in HCV-positive patients 1.

Real-World Evidence

The most recent and comprehensive evidence supports safety:

• A 2023 meta-analysis of 1,033 patients found an overall HCV reactivation rate of only 7% (95% CI 0.02-0.14) with biologic therapy 2. This rate varied by geography (8% in Asia vs 4% in Europe), suggesting the risk is relatively low but warrants monitoring.

• A 2022 Italian multicenter study of 30 HCV antibody-positive patients (all HCV-RNA negative) treated with various biologics, including anti-IL-23 agents, found no evidence of viral reactivation during follow-up 3. This is particularly reassuring for newer biologics.

• A 2021 multicenter cohort study of 61 HCV-positive patients (112 treatment episodes) found 14 reactivation episodes but identified no significant predictors for HCV reactivation, unlike HBV where specific risk factors were clear 4.

Clinical Algorithm for Management

Pre-Treatment Screening

1. Obtain serologic tests for hepatitis C antibody (required baseline screening per guidelines) 1
2. If HCV antibody-positive, check HCV-RNA viral load to distinguish:
   • Active infection (HCV-RNA positive)
   • Resolved infection (HCV-RNA negative)

For Active HCV Infection (HCV-RNA Positive)

• Consult with infectious disease or hepatology before initiating biologic therapy 1
• Consider treating HCV with direct-acting antivirals first (highly effective, well-tolerated, short duration)
• If psoriasis severity necessitates immediate treatment, biologics can be initiated with concurrent HCV treatment and close monitoring

For Resolved HCV Infection (HCV Antibody-Positive, HCV-RNA Negative)

• Biologics can be safely initiated without antiviral prophylaxis 3, 5
• No specialist consultation required unless other complicating factors exist

Ongoing Monitoring

• Monitor liver function tests (ALT, AST) at baseline and periodically (every 3-6 months recommended) 1
• Check HCV-RNA viral load every 6 months in previously HCV-RNA positive patients 6
• For patients with resolved infection, monitoring can be less frequent at physician discretion

Choice of Biologic Agent

IL-12/23 inhibitors (ustekinumab) and IL-23 inhibitors (risankizumab, guselkumab) appear safest based on guideline-specific endorsement and emerging evidence 1, 3, 6. These agents have the most favorable data in HCV-positive patients.

IL-17 inhibitors (secukinumab, ixekizumab) also demonstrate good safety profiles with minimal reactivation risk 7, 6.

TNF-α inhibitors can be used but require more caution and closer monitoring, as they carry theoretical higher immunosuppression risk 1.

Critical Caveats

• HCV antibody positivity alone does not contraindicate biologic therapy - the key distinction is whether active viral replication exists (HCV-RNA status)
• The reactivation risk with HCV is substantially lower than with HBV, where specific prophylaxis protocols are mandatory
• Most reported reactivations occurred in patients who did not receive appropriate screening or monitoring 7
• Do not confuse HCV with HBV management - HBV requires antiviral prophylaxis in many scenarios, while HCV typically does not

Bottom Line

Biologic therapy is both FDA-approved and clinically safe for HCV antibody-positive patients with severe plaque psoriasis. The evidence supports proceeding with treatment after appropriate screening, with preference for IL-12/23 or IL-23 inhibitors, and implementing regular monitoring for viral reactivation and liver function.